-
Product Insights
NewDermatomyositis – Drugs In Development, 2024
Empower your strategies with our Dermatomyositis – Drugs In Development, 2024 report and make more profitable business decisions. Dermatomyositis is a rare inflammatory disease characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids. The Dermatomyositis drugs in development market research report provide comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage...
-
Product Insights
NewHemolytic Uremic Syndrome – Drugs In Development, 2024
Empower your strategies with our Hemolytic Uremic Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Hemolytic uremic syndrome (HUS) is a rare but serious condition that affects the blood vessels and kidneys. It is caused by the damage and inflammation of small blood vessels, which leads to the formation of blood clots that block the flow of blood and oxygen to the organs. HUS can result in anemia, low platelet count, and kidney failure. The most...
-
Product Insights
NewAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2024
Empower your strategies with our Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2024 report and make more profitable business decisions. Anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitis is a group of autoimmune diseases that cause inflammation and damage to small blood vessels. It is triggered by autoantibodies called ANCAs that target and attack neutrophils, a type of white blood cell. ANCA vasculitis can affect different organs or parts of the body, such as the skin, kidney, or lung. The symptoms,...
-
Product Insights
NewAtypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) – Drugs In Development, 2024
Empower your strategies with our Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in the small blood vessels in the kidneys. Symptoms include vomiting, abdominal pain, pale skin tone, fatigue and irritability, blood in the urine, and confusion. The Atypical...
-
Product Insights
NewNeuromyelitis Optica (Devic’s Syndrome) – Drugs In Development, 2024
Empower your strategies with our Neuromyelitis Optica (Devic's Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Neuromyelitis optica (NMO), also known as Devic's syndrome, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord, or nerves. NMO is an autoimmune condition where the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness, and bladder/bowel problems. The Neuromyelitis Optica (Devic's Syndrome) drugs in development market research report provide...
-
Product Insights
NewKidney Transplant Rejection – Drugs In Development, 2024
Empower your strategies with our Kidney Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter, and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ...
-
Product Insights
NewHemoglobinuria – Drugs In Development, 2024
Empower your strategies with our Hemoglobinuria – Drugs In Development, 2024 report and make more profitable business decisions. Hemoglobinuria is a condition characterized by the presence of free hemoglobin in the urine. Hemoglobin is the protein in red blood cells responsible for transporting oxygen throughout the body. When red blood cells break down, the released hemoglobin can be filtered by the kidneys and appear in the urine, giving it a red or brown color. Hemoglobinuria can result from various conditions, including...
-
Product Insights
NewParoxysmal Nocturnal Hemoglobinuria – Drugs In Development, 2024
Empower your strategies with our Paroxysmal Nocturnal Hemoglobinuria – Drugs In Development, 2024 report and make more profitable business decisions. Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier than normal. Symptoms include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache, and shortness of breath. The predisposing factors include age, obesity, and hormone therapy. Treatment includes surgery, chemotherapy, and radiation therapy. The Paroxysmal Nocturnal Hemoglobinuria drugs in development market research report provide...
-
Product Insights
NewLupus Nephritis – Drugs In Development, 2024
Empower your strategies with our Lupus Nephritis – Drugs In Development, 2024 report and make more profitable business decisions. Lupus nephritis is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects various organs, tissues, and systems within the body. Lupus nephritis specifically involves inflammation of the kidneys, leading to kidney damage and impaired kidney function. In systSLE, the body's immune system mistakenly attacks its own tissues and organs, including the kidneys, causing inflammation. Not all individuals with...